ARDEA BIOSCIENCES, INC.

🇺🇸United States

Country: 🇺🇸United States

Ownership: Subsidiary

Established: 1994-01-01

Employees: 107

Market Cap: -

Website: http://www.ardeabio.com

Clinical Trials

RDEA3170 and Febuxostat Combination Study in Gout Subjects

Phase 2

Completed

Conditions: Gout

Interventions: Drug: RDEA3170 10 mg
Drug: RDEA3170 15 mg
Drug: RDEA3170 2.5
Drug: RDEA3170 5 mg
Drug: Febuxostat 40 mg
Drug: Febuxostat 80 mg

First Posted Date: 2014-09-23

Last Posted Date: 2017-07-27

Lead Sponsor: Ardea Biosciences, Inc.

Target Recruit Count: 64

Registration Number: NCT02246673

Mild, Moderate and Severe Renal Impairment Study

Phase 1

Completed

Conditions: Gout

Interventions: Drug: RDEA3170

First Posted Date: 2014-08-19

Last Posted Date: 2017-04-25

Lead Sponsor: Ardea Biosciences, Inc.

Target Recruit Count: 31

Registration Number: NCT02219516

Lesinurad Tablet Bioequivalence

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: Lesinurad 400 mg (manufactured at Site 1)
Drug: Lesinurad 400 mg (manufactured at Site 2)

First Posted Date: 2014-05-01

Last Posted Date: 2014-09-22

Lead Sponsor: Ardea Biosciences, Inc.

Target Recruit Count: 54

Registration Number: NCT02127775

Bioavailability of Lesinurad and Intravenous [14C]Lesinurad

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: Lesinurad 400 mg
Drug: [14C]lesinurad (100 μg per 10 mL)

First Posted Date: 2014-01-20

Last Posted Date: 2014-05-20

Lead Sponsor: Ardea Biosciences, Inc.

Target Recruit Count: 10

Registration Number: NCT02039700

Metformin and Furosemide Drug-Drug Interaction Study

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: Lesinurad 400 mg
Drug: Metformin 850 mg
Drug: Furosemide 40 mg

First Posted Date: 2014-01-07

Last Posted Date: 2014-02-14

Lead Sponsor: Ardea Biosciences, Inc.

Target Recruit Count: 23

Registration Number: NCT02028689

Lesinurad Tablet Relative Bioavailability

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: Lesinurad 400 mg (Site 1)
Drug: Lesinurad 400 mg (Site 2, Lot A)
Drug: Lesinurad 400 mg (Site 2, Lot B)

First Posted Date: 2013-11-18

Last Posted Date: 2014-09-22

Lead Sponsor: Ardea Biosciences, Inc.

Target Recruit Count: 36

Registration Number: NCT01986556

Antacid Interaction Study

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: Lesinurad 400 mg
Drug: Tums 500 mg and 750 mg
Drug: MINTOX 10 mL

First Posted Date: 2013-11-13

Last Posted Date: 2014-05-20

Lead Sponsor: Ardea Biosciences, Inc.

Target Recruit Count: 24

Registration Number: NCT01982201

RDEA3170 Monotherapy in Subjects With Gout

Phase 2

Completed

Conditions: Gout

Interventions: Drug: RDEA3170 5 mg
Drug: RDEA3170 10 mg
Drug: RDEA3170 12.5 mg
Drug: Placebo

First Posted Date: 2013-08-22

Last Posted Date: 2015-07-01

Lead Sponsor: Ardea Biosciences, Inc.

Target Recruit Count: 172

Registration Number: NCT01927198

RDEA3170 AME Study

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: RDEA3170 10 mg

First Posted Date: 2013-07-29

Last Posted Date: 2014-01-09

Lead Sponsor: Ardea Biosciences, Inc.

Target Recruit Count: 8

Registration Number: NCT01910506

Lesinurad Interaction Study With Ranitidine

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: lesinurad 400 mg
Drug: ranitidine 150 mg
Drug: lesinurad 400 mg + ranitidine 150 mg

First Posted Date: 2013-07-25

Last Posted Date: 2014-01-09

Lead Sponsor: Ardea Biosciences, Inc.

Target Recruit Count: 16

Registration Number: NCT01908257

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy